Hepatology

Top Story

LT candidates experience decreased physical function while waitlisted

February 11, 2016

Liver transplantation candidates with cirrhosis experienced significant decline in physical functioning while waitlisted for transplant. This decreased function was also associated with increased risk for mortality, according to data published in Hepatology.

“We hypothesized that liver transplant candidates experience accelerated function decline and that the trajectory of change in physical function is associated with waiting list mortality, independent of baseline physical function,” Jennifer C. Lai, MD, of the division of gastroenterology and hepatology, University of California San Francisco, and colleagues wrote.

In the Journals

Health care rates, costs high in HCV/HIV patients who failed prior treatment

February 11, 2016
In a retrospective cohort study, patients with HCV/HIV co-infection with mild infection who did not achieve sustained virologic response from previous therapy for HCV…
In the Journals

Victoza reduces BMI, other variables in NASH

February 10, 2016
Researchers found that Victoza successfully reduced BMI, cholesterol-low density lipoprotein and other clinical variables in patients with nonalcoholic steatohepatitis…
In the Journals

Faldaprevir yields high SVR in relapsers with HCV genotype 1

February 10, 2016
Treatment with faldaprevir plus pegylated interferon alfa-2b and ribavirin was efficacious among patients with hepatitis C virus genotype 1 infection who relapsed on a…

Tobira completes enrollment of ORION study for NAFLD, obesity

February 10, 2016
Tobira Therapeutics announced it has completed patient recruitment and enrollment for its phase 2a ORION clinical trial, which will be investigating the safety and…
More News Headlines »
CME

Case Challenges in Pediatric Fatty Liver: What to Look For and When to Refer

This activity is supported by an educational grant from Synageva BioPharma Corp.

Non-alcoholic fatty liver disease (NAFLD) is characterized by excess fat deposition in the liver due to causes other…
More »
Meeting News CoverageVideo

VIDEO: Defibrotide effective, well tolerated in patients with hepatic veno-occlusive disease

January 3, 2016
More »
Featured
CME

HCV VOICE II: Optimizing Virological Outcomes with Integrated HCV Education

This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
Current Issues Current Issues
View the Current Issue
HCV Next
morganatic-roan morganatic-roan